New research out of England published in The Lancet Infectious Diseases suggests that hospitalization and visits to the emergency department are twice as likely with the variant of concern (VOC) Delta compared to the Alpha variant.
As the world – and Canada – deals with increasing case numbers due to variants, scientists from the Imperial College London provide a snapshot of emerging data on real-life efficacy of COVID-19 vaccines against variants.
In their recent publication in The New England Journal of Medicine, researchers Dr. Kashir Ali, Dr. Gary Berman and colleagues presented the interim results of the Moderna vaccine trial in adolescents aged 12 to 17.
Researchers from Ontario indicate that about 80% of students enrolled at a large Canadian university between June and October 2020, prior to the availability of vaccines, intended to receive a COVID-19 vaccine once it was offered.
A new study published in The Lancet by researchers from Oxford University provides more in-depth safety and immunogenicity data to support a “mix-and-match” vaccine strategy, similar to the one currently used in Canada.
According to a recent viewpoint in Science, around one in three people with symptomatic COVID-19 still experience symptoms 12 weeks after the onset of infection, an outcome known as Post-COVID Conditions or Long COVID.